



## Clinical trial results:

**A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals' MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to 15 years, previously primed with a MenC conjugate vaccine.**

### Summary

EudraCT number	2013-004778-84
Trial protocol	SE ES
Global end of trial date	18 June 2014

### Results information

Result version number	v1 (current)
This version publication date	23 December 2018
First version publication date	23 December 2018
Summary attachment (see zip file)	Cancelled before active statement (Cancelled before Active Statement.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	116775
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	18 June 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 June 2014
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

Main objective of the trial:

To evaluate the vaccine response induced by one dose of MenACWY-TT administered to MenC-primed and MenC unprimed subjects.

Protection of trial subjects:

The study was cancelled before active (see attached statement). No patient entered the study, therefore no results / data are available.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 June 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Spain: 49999
Country: Number of subjects enrolled	Sweden: 50000
Worldwide total number of subjects	99999
EEA total number of subjects	99999

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	50000
Adolescents (12-17 years)	49999
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

99999 is "Not applicable" value or 0 participants, the study was cancelled before active. No patient entered the study, therefore no results / data are available.

### Pre-assignment

Screening details:

Study cancelled before active (see attached statement)

### Period 1

Period 1 title	Cancelled before active period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not blinded

### Arms

Arm title	No-Arm
Arm description: -	
Arm type	cancelled before active
Investigational medicinal product name	study cancelled before active
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution and suspension for suspension for injection in pre-filled syringe
Routes of administration	Route of administration not applicable

Dosage and administration details:

cancelled before active

<b>Number of subjects in period 1</b>	No-Arm
Started	99999
Completed	0
Not completed	99999
study was cancelled before active	99999

## Baseline characteristics

---

### Reporting groups

Reporting group title	Cancelled before active period
-----------------------	--------------------------------

Reporting group description: -

Reporting group values	Cancelled before active period	Total	
Number of subjects	99999	99999	
Age categorical			
Units: Subjects			
Adolescents	99999	99999	
Gender categorical			
Units: Subjects			
Female	50000	50000	
Male	49999	49999	

## End points

### End points reporting groups

Reporting group title	No-Arm
Reporting group description: -	

### Primary: No endpoint results

End point title	No endpoint results <sup>[1]</sup>
End point description:	

End point type	Primary
----------------	---------

End point timeframe:

The study was cancelled before active (see attached statement)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The study was cancelled before active (see attached statement).

<b>End point values</b>	No-Arm			
Subject group type	Reporting group			
Number of subjects analysed	99999			
Units: Participants	0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

The study was cancelled before active (see attached statement)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

---

Frequency threshold for reporting non-serious adverse events: 0 %

---

### Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The study was cancelled before active (see attached statement).

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
18 June 2014	The study was cancelled before active (see attached statement).	-

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported
---------------

Notes: